Form 8-K Jazz Pharmaceuticals For: Feb 08
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Jazz Pharmaceuticals (JAZZ) PT Lowered to $175 at Oppenheimer as Erwinaze Deal Terminated
February 12, 2019 12:26 PM ESTOppenheimer analyst Esther Rajavelu lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $175.00 (from $180.00) while maintaining a Outperform rating.
The analyst commented, "JAZZ announced the termination of its Erwinaze license agreement with Porton Biopharma Limited (PBL) at the expiration of the current term... More
